Latest news for Entest Group (OTC:ETNI) Stock

Entest Group Inc

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) directors Kimbal Musk and Robyn M Denholm as well as Chief Financial Officer Vaibhav Taneja sold shares of the company over the past week, according to recent filings with the Securities and Exchange Commission.
What Happened: According to a filing dated Feb. 3, Denholm, Director of Tesla and board chair, sold 112,390 shares of the company worth about $43.2 million.
Taneja on the same day sold 7,000 shares worth $2.8 million. 
The filings noted that the transactions by both Taneja and Denholm are part of a trading plan adopted last year. Both acquired the shares they sold as part of a stock option plan.
Tesla board member and Elon Musk&#8217;s brother Kimbal Musk, meanwhile, sold 75,000 shares worth $27.6 million a few days later on Feb. 6. Unlike Denholm and Taneja, this is Musk&#8217;s first sale of securities in the past three months.
Price Action: Tesla stock closed down 1% on Thursday at $374.32. The stock is up by about 100% over the past year, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43552235/tesla-hikes-model-x-price-by-5000-making-it-more-expensive-than-cybertruck" target="_blank" rel="noreferrer noopener">Tesla Hikes Model X Price By $5000, Making It More Expensive Than Cybertruck</a></li>
</ul>
Photo courtesy: Shutterstock

News

Tech

TSLA

Elon Musk's Brother Kimbal Musk And Other Tesla Execs Sell Over $73 Million In Stock

Needham analyst Mayank Tandon maintains SS&amp;C Techs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) with a Buy and raises the price target from $90 to $105.

Price Target

Analyst Ratings

SSNC

Needham Maintains Buy on SS&C Techs Hldgs, Raises Price Target to $105

The Company currently intends to use the net proceeds of this offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures.

Offerings

STIM

Neuronetics Prices Public Offering Of 8M Shares Of Common Stock At $2.25 Per Share, Resulting In Gross Proceeds Of $18M

Rosenblatt analyst Hans Mosesmann maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Neutral and lowers the price target from $880 to $800.

MPWR

Rosenblatt Maintains Neutral on Monolithic Power Systems, Lowers Price Target to $800

Management

Hilton Grand Vacations Names Erin Day, Its Executive Vice President Of Finance, As Acting CFO, Effective Immediately

Hilton Grand Vacations Says CFO Daniel J. Mathewes Is Taking Temporary Leave Of Absence For Personal Reasons, Effective Immediately - Filing

Rosenblatt analyst Hans Mosesmann maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $90 to $70.

MCHP

Rosenblatt Maintains Buy on Microchip Technology, Lowers Price Target to $70

Needham analyst Mike Cikos maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Buy and raises the price target from $160 to $185.

Needham Maintains Buy on Cloudflare, Raises Price Target to $185

On Thursday, Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) reached an agreement for the early settlement of certain prepaid variable share forward transactions related to shares of Cencora, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>).
As part of the early settlement, Walgreens Boots will transfer approximately 6.1 million Cencora shares to the financial institutions and make a net cash payment of about $20 million.
Alongside this, the company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The company receives approximately&nbsp;$300 million&nbsp;from the early settlement and the concurrent sale of shares.
Following this settlement, WBA retains 12.6 million Cencora shares under remaining prepaid contracts, set to mature primarily in March, June, and September 2025, with the potential for additional cash proceeds.
The proceeds will primarily be used for debt reduction and general corporate purposes.&nbsp;&nbsp;The transactions were scheduled to mature in March and June 2026.
By settling early and executing a concurrent share sale, WBA is realizing the embedded cash value of the prepaid variable share forwards. With this settlement, Walgreens has lowered its stake in Cencora from 10% to 6%.
Notably, Walgreens has been cutting its stake in Concera for the last few years, decreasing the stake from 12% to 10% for around <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40119033/walgreens-boots-alliance-sells-shares-of-cencora-for-approximately-1-1-billion-of-proceeds" rel="noreferrer noopener">$1.1 billion in August 2024</a>.
Also, in May 2024,&nbsp;Walgreens reduced ownership of Cencora shares from 13% to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38975615/walgreens-boots-alliance-sells-shares-of-cencora-for-400-million-of-proceeds" rel="noreferrer noopener">12% for approximately $400 million</a>.
These transactions, along with other recent measures such as the dividend suspension, further strengthen WBA&#8217;s ability to address its upcoming debt maturities in fiscal 2026.
Last month, the company announced it is halting its quarterly dividend while the management team reviews and adjusts its capital allocation strategy to match the company&#8217;s <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43397182/whats-going-on-with-walgreens-shares-friday-2" rel="noreferrer noopener">broader long-term recovery efforts</a>.
Investors can gain exposure to the stock via Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEY#NASDAQ">PEY</a>) and Invesco S&amp;P 500 Equal Weight Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSPS#NYSE">RSPS</a>).
Price Action: WBA shares are up 0.40% at $10.09 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43390001/feds-favorite-inflation-gauge-rises-as-predicted-consumer-spending-jumps-at-fastest-pace-in-9-months" target="_blank" rel="noreferrer noopener">Fed&#8217;s Favorite Inflation Gauge Rises As Predicted, Consumer Spending Jumps At Fastest Pace In 9 Months</a></li>
</ul>
Image via Shutterstock.

Equities

Mid Cap

Movers

RSPS

Walgreens Cashes In: Slashes Cencora Stake Again In Debt-Fighting Move

Guidance

Newell Brands Sees Q1 Adjusted EPS Of ($0.09)-($0.06) Compared With Street View Of $0.02; Company Sees FY25 Adjusted EPS $0.70-$0.76 Compared With Street View $0.75

Needham analyst Mayank Tandon maintains Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) with a Buy and raises the price target from $55 to $65.

Needham Maintains Buy on Genpact, Raises Price Target to $65

Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) just disclosed its Q4 earnings on Friday, February 7, 2025 at 07:30 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Fortive beat estimated earnings by 4.0%, reporting an EPS of $1.17 versus an estimate of $1.12.
Revenue was up $36.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat on EPS by $0.04 which was followed by a 1.0% drop in the share price the next day.
Here's a look at Fortive's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.93</td>
<td>0.92</td>
<td>0.79</td>
<td>0.94</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.97</td>
<td>0.93</td>
<td>0.83</td>
<td>0.98</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.55B</td>
<td>1.57B</td>
<td>1.53B</td>
<td>1.56B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.53B</td>
<td>1.55B</td>
<td>1.52B</td>
<td>1.58B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Fortive management provided guidance for Q1 2025, expecting earnings between $0.83 and $0.86 per share.
To track all earnings releases for Fortive <a href="https://www.benzinga.com/quote/FTV/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Fortive Q4 Earnings Assessment

On Friday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with hemophilia A with and without inhibitors.
The <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915260" rel="noreferrer noopener">trial</a> initially assessed once-weekly prophylaxis treatment (regular treatment to prevent prolonged and spontaneous bleeding) with investigational Mim8 before giving participants the option to change to once-monthly dosing after 26 weeks.
In part one of the FRONTIER3 study, participants received once-weekly doses of Mim8 for 26 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026" rel="noreferrer noopener">Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026</a>
In part two, participants could continue with once-weekly dosing or move to once-monthly dosing for the remaining 26 weeks.
<ul>
<li>The interim analysis reports results after part one of the study, with some preliminary data shared from part two, which continued following this analysis.</li>
<li>For part one of the study in children on once-weekly prophylaxis, the estimated mean (average) annualized bleeding rate (ABR) for treated bleeds was 0.53.</li>
</ul>
The median ABR was zero; 74.3% of participants had zero treated bleeds.
All children with hemophilia A with inhibitors (n=14) reported zero treated bleeds. After completing the initial 26 weeks of the study, 45% of participants moved to once-monthly Mim8, and the rest (55%) remained on the once-weekly dose.
The data showed that Mim8 was well-tolerated and efficacious.
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.
In May 2024, Novo Nordisk released headline results from the FRONTIER 2 Phase 3a trial of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in hemophilia A patients 12 years or older <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38797768/novo-nordisks-hemophilia-candidate-can-prevent-bleeding-episodes-effectively-regardless-of-dosing" rel="noreferrer noopener">with or without inhibitors</a>.
The trial achieved its co-primary endpoints by demonstrating a statistically significant and superior reduction of treated bleeding episodes with both once-weekly and once-monthly Mim8 versus no prophylaxis treatment and prior coagulation factor prophylaxis treatment.
In June 2024,&nbsp;Novo Nordisk acquired the Hemophilia A program and rights to 2seventy Bio Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39532373/novo-nordisk-buys-2seventys-hemophilia-a-program-divestiture-supports-exclusive-focus-on-abecma" rel="noreferrer noopener">cells for autoimmune disease</a>.
Price Action: NVO stock is down 2.33% at $89.20 during the premarket session on last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43542288/block-poised-for-growth-in-2025-analyst-predicts-outperformance-and-possible-sp-500-spot" target="_blank" rel="noreferrer noopener">Block In The S&amp;P500? BofA Analyst Says Company Meets All Criteria</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

TSVT

Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data

The earnings results for Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) for Q4 were made public on Friday, February 7, 2025 at 07:30 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Cboe Global Markets missed estimated earnings by -1.0%, reporting an EPS of $2.1 versus an estimate of $2.12.
Revenue was up $25.50 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company beat on EPS by $0.03 in the previous quarter, leading to a 2.0% drop share price change the next day.
Here's a look at Cboe Global Markets's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.19</td>
<td>2.10</td>
<td>2.04</td>
<td>2.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.22</td>
<td>2.15</td>
<td>2.15</td>
<td>2.06</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>530.76M</td>
<td>514.51M</td>
<td>504.80M</td>
<td>511.68M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>532.00M</td>
<td>513.80M</td>
<td>502.10M</td>
<td>499.00M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Cboe Global Markets <a href="https://www.benzinga.com/quote/CBOE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBOE

Cboe Global Markets Earnings Report: Q4 Overview

Rosenblatt analyst Mike Genovese maintains Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) with a Buy and maintains $22 price target.

EXTR

Rosenblatt Maintains Buy on Extreme Networks, Maintains $22 Price Target

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Outperform and lowers the price target from $108 to $95.

Barrington Research Maintains Outperform on Haemonetics, Lowers Price Target to $95

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and maintains $80 price target.

Reiteration

CORT

HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $80 Price Target

Barrington Research analyst Alexander Paris maintains Perdoceo Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) with a Outperform and maintains $32 price target.

PRDO

Barrington Research Maintains Outperform on Perdoceo Education, Maintains $32 Price Target

Snap Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) CEO, Evan Spiegel, has taken a playful jab at Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) for its history of mimicking Snapchat&#8217;s features in a way that seems to mock the social media giant.
What Happened: Spiegel updated his LinkedIn profile that now read, &#8220;Loving husband, father of four boys, VP Product @ Meta,&#8221; indicates a Fortune <a href="https://fortune.com/2025/02/06/snap-ceo-evan-spiegel-mocks-mark-zuckerberg-meta-copycat-features/">report</a>. This update is widely interpreted as a swipe at Meta&#8217;s penchant for copying Snapchat&#8217;s features.
Despite Mark Zuckerberg&#8216;s&nbsp;$3 billion acquisition offer in&nbsp;2013, Spiegel has staunchly upheld Snap&#8217;s independence. Meta, in turn, has launched features remarkably similar to Snapchat&#8217;s, including Instagram Stories, disappearing direct messages, and face-distorting filters.
Spiegel, in a 2018 conference, shared mixed feelings about Meta&#8217;s imitation, stating, &#8220;It was the best feeling to design something that is so simple and so elegant that the only thing competitors can do is copy it exactly.&#8221; 
He also humorously suggested that Meta should replicate Snapchat&#8217;s data protection practices.
SEE ALSO: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43527542/meta-stock-soars-but-zuckerbergs-cashing-in-should-investors-worry">Meta Stock Soars, But Zuckerberg&#8217;s Cashing In &#8211; Should Investors Worry?</a>
Why It Matters: A CNBC report in Jan indicated that Meta is providing incentives to creators to advertise Instagram on competing short-form video platforms like TikTok, Snapchat, and YouTube to gain a larger share. This move highlights the intense competition in the social media space, as platforms battle for the attention of millions of users while TikTok&#8217;s future remains uncertain.
Meanwhile, Snap has been grappling with its own challenges. Despite reporting a fourth-quarter <a href="https://www.benzinga.com/25/02/43504595/snap-falls-despite-q4-beat-as-analysts-remain-cautious-on-ad-growth-and-higher-expenses">earnings beat</a>, Snap&#8217;s shares fell as analysts expressed concerns over ad growth and higher expenses.
Last week, Meta announced its fourth-quarter results, surpassing expectations for both revenue and earnings, while reaffirming its commitment to significant AI-related investments.
Snap has a much smaller user base when compared to Meta, but it has posted impressive growth for the fourth quarter. Meta&#8217;s Family Daily Active People (DAP)&nbsp;grew 5.5% year-on-year to 3.35 billion, while Snap&#8217;s Daily Active Users increased 9% year-over-year to 453 million. 
<ul>
<li>READ ALSO: <a href="https://www.benzinga.com/markets/25/02/43552448/pinterests-gen-z-boom-engagement-hits-62-all-time-high-as-advertiser-clicks-surge-90heres-whats-driving-the-growth-for-this-meta-rival">Pinterest&#8217;s Gen Z Boom: Engagement Hits All-Time High As Advertiser Clicks Surge 90%—What&#8217;s Working For The Meta Rival</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments

Entest Group

News

Latest news for Entest Group (OTC:ETNI) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga